Serologic testing of a panel of five antibodies in inflammatory bowel diseases: Diagnostic value and correlation with disease phenotype

Wang,Zhi‑Zhi; Shi,Ke; Peng,Jie

doi:10.3892/br.2017.860

Serologic testing of a panel of five antibodies in inflammatory bowel diseases: Diagnostic value and correlation with disease phenotype

Authors:
- Zhi‑Zhi Wang
- Ke Shi
- Jie Peng
View Affiliations

Affiliations: Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Laboratory of the Department of Gerontology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: February 17, 2017 https://doi.org/10.3892/br.2017.860
Pages: 401-410
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the diagnostic value of five serological antibodies, perinuclear antineutrophil cytoplasmic antibody (pANCA), anti‑Saccharomyces cerevisiae antibodies [ASCA; ASCA‑immunoglobulin (IgG)and ASCA‑IgA], Escherichia coli outer membrane porin C antibody (anti‑OmpC) and CBir1 flagellin antibody for detection in inflammatory bowel diseases. Whether the antibody status correlated with the disease phenotype was also evaluated. Sera from 71 patients with Crohn's disease (CD), 41 patients with ulcerative colitis (UC), 78 patients with other gastrointestinal diseases and 31 healthy control subjects were investigated. Clinical data were gathered at the time of serum sampling and enzyme‑linked immunosorbent assay was used to determine titers of the above mentioned five antibodies. The pANCA test exhibited a sensitivity of 53.7% for UC and the ASCA test had a sensitivity of 66.2% for CD. The prevalence of anti‑OmpC was significantly higher in CD than in intestinal tuberculosis (TB), indicating that anti‑OmpC may be a serologic marker distinguishing CD from TB. The pANCA+/ASCA‑ exhibited the best specificity for differentiating between CD and UC. In UC, the presence of pANCA was greater in the patients with moderate to severe activity than in those with mild activity. ASCA was more positive in ileal CD. Furthermore, positive ASCA‑IgG or anti‑OmpC implied that complicated CD and pANCA was associated with colonic CD. Seropositivity of anti‑CBir1 was lowest in colonic CD.

View Figures

View References

1	Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S, Gearry R, Goh KL, Hamid S, Khan AG, et al: World gastroenterology organization practice guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 16:112–124. 2010. View Article : Google Scholar : PubMed/NCBI
2	Zeng Z, Zhu Z, Yang Y, Ruan W, Peng X, Su Y, Peng L, Chen J, Yin Q, Zhao C, et al: Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: A prospective population-based study. J Gastroenterol Hepatol. 28:1148–1153. 2013. View Article : Google Scholar : PubMed/NCBI
3	Zhao J, Ng SC, Lei Y, Yi F, Li J, Yu L, Zou K, Dan Z, Dai M, Ding Y, et al: First prospective, population-based inflammatory bowel disease incidence study in mainland of China: The emergence of ‘western’ disease. Inflamm Bowel Dis. 19:1839–1845. 2013.PubMed/NCBI
4	Yang H, Li Y, Wu W, Sun Q, Zhang Y, Zhao W, Lv H, Xia Q, Hu P, Li H and Qian J: The incidence of inflammatory bowel disease in Northern China: A prospective population-based study. PLoS One. 9:e1012962014. View Article : Google Scholar : PubMed/NCBI
5	Ye L, Cao Q and Cheng J: Review of inflammatory bowel disease in China. Sci World J. 2013:2964702013. View Article : Google Scholar
6	Arai R: Serologic markers: Impact on early diagnosis and disease stratification in inflammatory bowel disease. Postgrad Med. 122:177–185. 2010. View Article : Google Scholar : PubMed/NCBI
7	Satsangi J, Silverberg MS, Vermeire S and Colombel JF: The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut. 55:749–753. 2006. View Article : Google Scholar : PubMed/NCBI
8	Best WR, Becktel JM, Singleton JW and Kern F Jr: Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology. 70:439–444. 1976.PubMed/NCBI
9	Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR and Parratt D: Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ. 297:1105–1106. 1988. View Article : Google Scholar : PubMed/NCBI
10	Peyrin-Biroulet L, Standaert-Vitse A, Branche J and Chamaillard M: IBD serological panels: Facts and perspectives. Inflamm Bowel Dis. 13:1561–1566. 2007. View Article : Google Scholar : PubMed/NCBI
11	Rump JA, Schölmerich J, Gross V, Roth M, Helfesrieder R, Rautmann A, Lüdemann J, Gross WL and Peter HH: A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology. 181:406–413. 1990. View Article : Google Scholar : PubMed/NCBI
12	Kim BG, Kim YS, Kim JS, Jung HC and Song IS: Diagnostic role of anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. Dis Colon Rectum. 45:1062–1069. 2002. View Article : Google Scholar : PubMed/NCBI
13	Zhou F, Xia B, Wang F, Shrestha UK, Chen M, Wang H, Shi X, Chen Z and Li J: The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China. Clin Chim Acta. 411:1461–1465. 2010. View Article : Google Scholar : PubMed/NCBI
14	Lawrance IC, Murray K, Hall A, Sung JJ and Leong R: A prospective comparative study of ASCA and pANCA in Chinese and caucasian IBD patients. Am J Gastroenterol. 99:2186–2194. 2004. View Article : Google Scholar : PubMed/NCBI
15	Papp M and Lakatos PL: Serological studies in inflammatory bowel disease: How important are they? Curr Opin Gastroenterol. 30:359–364. 2014. View Article : Google Scholar : PubMed/NCBI
16	Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J and Targan SR: Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 123:689–699. 2002. View Article : Google Scholar : PubMed/NCBI
17	Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, Geboes K, Bossuyt X, Vandewalle P, Oberhuber G, et al: The value of serologic markers in indeterminate colitis: A prospective follow-up study. Gastroenterology. 122:1242–1247. 2002. View Article : Google Scholar : PubMed/NCBI
18	Makharia GK, Sachdev V, Gupta R, Lal S and Pandey RM: Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis. Dig Dis Sci. 52:33–39. 2007. View Article : Google Scholar : PubMed/NCBI
19	Gologan S, Iacob R, Preda C, Vadan R, Cotruta B, Catuneanu M, Iacob S, Constantinescu I, Gheorghe L, Iobagiu S, et al: Higher titers of anti-Saccharomyces cerevisiae antibodies IgA and IgG are associated with more aggressive phenotypes in Romanian patients with Crohn's disease. J Gastrointestin Liver Dis. 21:39–44. 2012.PubMed/NCBI
20	Zholudev A, Zurakowski D, Young W, Leichtner A and Bousvaros A: Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: Diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 99:2235–2241. 2004. View Article : Google Scholar : PubMed/NCBI
21	Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW and Tekkis PP: Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 101:2410–2422. 2006. View Article : Google Scholar : PubMed/NCBI
22	Zhang Z, Li C, Zhao X, Lv C, He Q, Lei S, Guo Y and Zhi F: Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: A meta-analysis. Dig Dis Sci. 57:2944–2954. 2012. View Article : Google Scholar : PubMed/NCBI
23	Prideaux L, De Cruz P, Ng SC and Kamm MA: Serological antibodies in inflammatory bowel disease: A systematic review. Inflamm Bowel Dis. 18:1340–1355. 2012. View Article : Google Scholar : PubMed/NCBI
24	Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO and Hershberg RM: Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 128:2020–2028. 2005. View Article : Google Scholar : PubMed/NCBI
25	Kuna AT: Serological markers of inflammatory bowel disease. Biochem Med (Zagreb). 23:28–42. 2013. View Article : Google Scholar : PubMed/NCBI
26	Cioffi M, Rosa AD, Serao R, Picone I and Vietri MT: Laboratory markers in ulcerative colitis: Current insights and future advances. World J Gastrointest Pathophysiol. 6:13–22. 2015. View Article : Google Scholar : PubMed/NCBI
27	Wang X and Dong E: Anti-neutrophil cytoplasmic antibodies in patients with inflammatory bowel diseases. Chin J Integr Med. 3:15–18. 2000.(In Chinese).
28	Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A and Shoenfeld Y: Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 54:1232–1236. 2005. View Article : Google Scholar : PubMed/NCBI
29	Devlin SM and Dubinsky MC: Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD. Inflamm. Bowel Dis. 14:125–128, 132–133. 2008. View Article : Google Scholar